LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and sells products across two core segments: Cardiopulmonary and Neuromodulation. Revenue comes from the sale of implantable and surgical devices used in cardiac surgery and neurological treatment. LivaNova is incorporated in the United Kingdom and operates globally, with ordinary shares listed on the Nasdaq Global Select Market. The company initiated a 2024 Restructuring Plan during the first quarter of FY2024 to sharpen focus on its Cardiopulmonary and Neuromodulation segments. Capital structure includes $345.0 million aggregate principal of 2.50% unsecured convertible senior notes due 2029, issued by subsidiary LivaNova USA, Inc., as well as a First Lien Credit Agreement with Goldman Sachs Bank USA entered into on August 13, 2021. The 2025 Notes, originally $287.5 million aggregate principal at 3.00%, were substantially repurchased using proceeds from the 2029 Notes issuance.

Revenue model

Transactional sales of medical devices, with revenue generated through the sale of Cardiopulmonary and Neuromodulation products to hospitals and healthcare providers.

Products and services

Cardiopulmonary devices used in cardiac surgery; Neuromodulation implantable devices for neurological conditions. Specific product names are not detailed in the available filing excerpts.

Customers and end markets

Hospitals and surgical centers in cardiac and neurology end markets. Specific customer concentration data is not available in the filing excerpts provided.

Value-chain role

Medical device manufacturer and direct seller to healthcare institutions.

Geographic exposure

Global operations; incorporated in the United Kingdom with U.S. subsidiary LivaNova USA, Inc. Specific revenue geographic breakdown is not available in the filing excerpts provided.

Source: SEC 10-K, filed 2026-02-25

Industry: Electromedical & Electrotherapeutic Apparatus